Aclaris Therapeutics
ACRS
109 hedge funds and large institutions have $144M invested in Aclaris Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 12 closing their positions.
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
69% more call options, than puts
Call options by funds: $83K | Put options by funds: $49K
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
11% more funds holding
Funds holding: 98 → 109 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
34% less capital invested
Capital invested by funds: $217M → $144M (-$73.2M)
36.58% less ownership
Funds ownership: 122.49% → 85.9% (-37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.64M |
| 2 |
DC
Decheng Capital
Menlo Park,
California
|
+$3.79M |
| 3 |
BG
Bollard Group
Boston,
Massachusetts
|
+$3.04M |
| 4 |
Morgan Stanley
New York
|
+$2.87M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$6.99M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$5.91M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.47M |
| 4 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$1M |
| 5 |
EAM
Exome Asset Management
New York
|
-$966K |
ACRS Hedge Fund Activity: Q1 2025 in Review
109 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2025, worth a combined $144M — down 34% from $217M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ACRS positions and 12 closed out — a net gain of 11 holders — while 39 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.64M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.99M sold.
- 109 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2025, up from 98 in Q4 2024.
- Funds reported $144M of Aclaris Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 23 funds opened new Aclaris Therapeutics positions in Q1 2025 and 12 closed out, a net change of +11 holders.
- The largest Aclaris Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $4.64M added.
- The largest Aclaris Therapeutics seller in Q1 2025 was Janus Henderson Group, an estimated $6.99M sold.
Based on aggregated 13F filings for Q1 2025.